Business Wire

Radisys Expands Access Portfolio with the Launch of Connect Open Broadband

21.5.2020 10:22:00 EEST | Business Wire | Press release

Share

Radisys® Corporation, a global leader of open telecom solutions, today introduced Connect Open Broadband, a carrier-grade, Tier 1 network-hardened, scalable and secure software-defined Passive Optical Network (PON) distribution based on open standards and web-scale architecture to drive rapid innovation and economies of scale. The disaggregated PON solution gives Communications Service Providers (CSPs) deployment flexibility, scalable network growth, and increased service agility with optimized CapEx and OpEx.

News Highlights

  • The demand for high-speed broadband services such as internet, video calling and conferencing, and IPTV has created massive growth in network data usage like never before. As such, CSPs’ networks are increasingly overburdened. Service providers need to optimize their networks to scale service delivery efficiently, while maximizing the opportunity to deliver innovation at a rapid pace.
  • Radisys’ Connect Open Broadband offers an intelligent, scalable and secure software-defined PON distribution based on the Open Networking Foundation’s (ONF) SEBA reference platform and enhanced with Radisys innovation. This architecture allows for a seamless introduction of the Broadband Forum’s OB-BAA architecture by conforming to the standard YANG models with the Northbound Interface (NBI).
  • The solution disaggregates software from the underlying hardware with open interfaces, enabling faster product innovation cycles. The hardware agnostic solution enables service providers to leverage white-box optical line terminals (OLTs) from an interoperable multi-vendor ecosystem for flexible deployable options.
  • Connect Open Broadband, built on cloud-native microservices architecture, allows for the addition of new network functions on demand and delivers a path to automated and simplified network operation. The programmability, automation and deeper network visibility further enables better fault detection, faster service delivery and future-proof network expansions.
  • The solution is access network (GPON, XGS-PON, NG-PON2) agnostic and offers flexible deployment options.

“In the digital era where high-bandwidth services and pervasive connectivity are required to meet subscriber expectations, service providers are rethinking how they build their networks to meet demand with optimal performance and value,” said Harris Razak, senior vice president of Broadband Access, Radisys. “Connect Open Broadband is a commercially ready, network-hardened solution that allows service providers to enable rapid innovation through disaggregation and to bring new services to market faster.”

“Radisys has been a Partner Member of ONF for many years and has been one of the most active supply chain members working directly with our operator partners. Radisys has helped drive ONF open reference designs and open source platforms and is among the first to commercialize solutions based on ONF platforms,” said Guru Parulkar, Executive Director, ONF. “Radisys’ Connect Open Broadband combines open architectures, software innovation, and white-box hardware to facilitate service agility.”

“Broadband service providers face increased pressure to deliver innovative services to compete with OTT providers,” said Simon Stanley, Analyst at Large, Heavy Reading. “Open, disaggregated solutions give service providers the flexibility to select best-in-class network elements from a number of vendors in order to intelligently scale their networks and deliver the services their customers demand in a cost-effective manner.”

Resources:

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye